Spondyloarthritis & psoriatic arthritis
Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
Authors' conclusion
Sustained BASDAI < 3 may be a valid and feasible target for a treat-to-target strategy in axSpA having function as treatment goal.
Study context
- Population
- axSpA patients receiving infliximab or golimumab in the Biologic Treatment Registry Across Canada (BioTRAC) registry, Canada, 2006–2017
- Participants
- 810 patients
- Exposure
- Sustained vs single-time-point vs no low disease activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS)) as predictors of sustained low Bath Ankylosing Spondylitis Functional Index (BASFI)
- Outcome
- Sustained low BASFI (<3) between 12 and 18 months
- Follow-up
- 12 and 18 months
Methodological detailsmulticentre, registry, generalized estimating equations
- Multicentre
- Registry
- Generalized estimating equations
Main finding
As reported in the abstract
Predictors of sustained low BASFI
- Sustained low BASDAI (multivariable generalized estimating equations (GEE))
- p < 0.001
- Low BASDAI only at 6 or 12 months (multivariable GEE)
- p = 0.001
- Baseline BASFI (multivariable GEE)
- p < 0.001
- Sustained ASDAS-ID (forced into model)
- p = 0.040
- Sustained ASDAS-LDA (forced into model)
- p < 0.001
Observational data: associations, not effects.
Further findings
Achievement of sustained low disease states
- Sustained low BASDAI
- 33.7%
- Sustained ASDAS-ID
- 13.4%
- Sustained ASDAS-LDA
- 24.7%
BASFI score at 18 months
- Similar results to sustained low BASFI analysis
Original publication
Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this? Arthritis Res Ther. Published 28 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →